Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Support

This activity is supported by an educational grant from Takeda Oncology.

Oncology Consultations®: Challenging the Experts on How They Treat and Individualize Care in NSCLC with ALK Inhibitors

Release Date: October 26, 2021
Expiration Date: October 26, 2022

Activity Overview

This Oncology Consultations® is a video-based program in which 2 experts use a case-based approach to discuss the treatment and management of non–small cell lung cancer (NSCLC). In this activity the faculty focus on the current and emerging therapeutic strategies for the management of ALK-positive NSCLC across lines of care. This engaging format is designed to help clinicians identify best practices in the diagnosis and management of lung cancer and to improve outcomes for their patients with this disease.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Takeda Oncology.

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.

Target Audience

This educational program is directed toward medical oncologists, pathologists, and pulmonologists interested in the treatment of advanced NSCLC. Other allied health care professionals, including nurse practitioners, physician assistants, nurses, and other health care professionals involved in the treatment and management of patients with advanced NSCLC, will also be invited to participate.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Apply evolving testing strategies to decision making, and ultimately therapeutic selection for frontline and subsequent management of patients with advanced ALK-positive NSCLC
  • Explain recent evidence on ALK inhibitor approaches from trials that evaluated these strategies among patients with advanced NSCLC in front-line and relapsed disease settings
  • Outline sequencing strategies for patients with advanced ALK-positive NSCLC to address treatment resistance and manage brain metastases
  • Create preemptive strategies to mitigate and manage adverse events associated with ALK inhibitors in multiple lines of care among patients with advanced NSCLC

Faculty, Staff, and Plannrs’ Disclosures

The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies. 


Yelena Y. Janjigian, MD
Justin F. Gainor, MD
Director, Center for Thoracic Cancers
Director, Targeted Immunotherapy
Associate Professor of Medicine
Massachusetts General Hospital
Harvard Medical School
Boston, MA

Disclosures: Consultant: Bristol Myers Squibb, Genentech, Ariad/Takeda, Loxo, Pfizer, Incyte, Novartis, Merck, Agios, Amgen, Jounce, Karyopharm, GlydeBio, EMD Serono, Mirati, AstraZeneca, Regeneron, Oncorus, Helsinn, Jounce, Array, and Clovis Oncology; Research Support: Novartis, Genentech/Roche, and Ariad/Takeda, Tesaro, Moderna, Blueprint, Scholar Rock, Bristol Myers Squibb, Jounce, Array, Adaptimmune, Novartis, Genentech/Roche, Alexo and Merck; Other: Immediate faculty member who is an employee and owns stock in Ironwood Pharmaceuticals.

Maurice Pérol, MD
Vincent Lam, MD
Assistant Professor
Upper Aerodigestive Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, MD

Disclosures: Consultant: Takeda

PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.


Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By